New Blood Test Promises Earlier Detection of Prostate Cancer
A promising new blood test could help doctors detect high-risk prostate cancer cases sooner than before. This test, known as Stockholm3, has shown better results than the traditional prostate-specific antigen (PSA) test in recent clinical trials.
In a study published in the Annals of Internal Medicine, researchers at the Karolinska Institutet in Sweden examined over 12,000 men aged 50 to 74, primarily from Sweden and Europe. Each participant underwent both the PSA test and the Stockholm3 test and was monitored for two years. By the end of the study, 443 men had been diagnosed with aggressive prostate cancer.
The findings revealed that Stockholm3 was able to identify 90% of the aggressive cases, compared to just 74% for the PSA test.
Improved Detection Rates
Researcher Thorgerdur Palsdottir emphasized that one of the main challenges in dealing with prostate cancer is recognizing which cases are truly dangerous. In her statement, she noted that Stockholm3 identifies significantly more aggressive cancer cases without leading to unnecessary follow-ups. This could change how prostate cancer screening is performed, allowing for earlier detection and fewer additional tests that may not be needed.
The Need for Change
Dr. Hari Vigneswaran, a co-author of the study and chief medical officer of A3P Biomedical, which developed Stockholm3, highlighted the limitations of the PSA test. He pointed out that while PSA has been the standard since the 1990s, it often results in unnecessary and costly follow-ups and can miss many cases of aggressive cancer.
He noted that early detection is crucial for effective treatment, with the five-year survival rate for aggressive prostate cancer confined to the prostate nearly reaching 100%.
Limitations and Future Plans
While the Stockholm3 test is showing promise, it is still under investigation and not yet available for purchase in the U.S. The test estimates a man’s risk of aggressive prostate cancer, but a biopsy is still necessary to confirm the diagnosis.
The company plans to apply for FDA approval to make the test available for routine screenings and aims to collect additional evidence to support this path, including data from U.S. patients.
Conclusion
The Stockholm3 test offers hope for more effective prostate cancer screening, potentially reducing the need for unnecessary MRIs and biopsies. As researchers continue to explore its effectiveness, it could prove to be a game-changer in early cancer detection.
